Enarodustat
Clinical data
Trade namesEnaroy
Other namesJTZ-951
Legal status
Legal status
  • Rx-only (Japan)
Identifiers
  • 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H16N4O4
Molar mass340.339 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
  • InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
  • Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).[1]

The drug was approved in September 2020 in Japan for anemia associated with CKD[2] and is currently in clinical development in the United States and South Korea.[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.[4]

References

  1. ↑ Hirota K (April 2021). "HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review". Biomedicines. 9 (5): 468. doi:10.3390/biomedicines9050468. PMC 8146675. PMID 33923349.
  2. ↑ "JT Receives Manufacturing and Marketing Approval of ENAROY Tablets 2mg･4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan" (PDF) (Press release). September 25, 2020.
  3. ↑ Markham A (January 2021). "Enarodustat: First Approval". Drugs. 81 (1): 169–174. doi:10.1007/s40265-020-01444-3. PMID 33320297. S2CID 229163684.
  4. ↑ "Enarodustat - Japan Tobacco". Adis Insight.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.